==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb


Details of Th1050 which contains 3 entries.


Entry 1
(1) Primary information
ID1358
ThPP IDTh1050
Therapeutic Peptide/Protein NamePegademase bovine
SequenceMAQTPAFNKPKVELHVHLDGAIKPETILYYGRKRGIALPADTPEELQNII view full sequnce in fasta
Functional ClassificationIa
Molecular Weight40788.2
Chemical FormulaC1821H2834N484O552S14
Isoelectric Point5.33
Hydrophobicity-0.428
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionBovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life.
Indication/DiseaseFor treatment of adenosine deaminase deficiency
PharmacodynamicsUsed to replace deficient or inactive adenosine deaminase which leads to severe combined immunodeficiency disease (SCID). The enzyme is responsible for converting adenosine to inosine. In the absence of adenosine deaminase, the purine substrates adenosine 2-deoxyadenosine and their metabolites are actually toxic to lymphocytes thereby leading to diminished immune function.
Mechanism of ActionPegademase converts adenosine (toxic) to inosine (less toxic) by deamination. It also converts 2'-deoxyadenosine to 2'-deoxyinosine via deamination.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesEnzyme Replacement Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionKrystexxa (pegloticase)
TargetAdenosine,Growth factor receptor-bound protein 2
Information of corresponding available drug in the market
Brand NameAdagen
CompanyEnzon Inc.
Brand DiscriptionAdagen is a modified enzyme. It is a conjugate of numerous strands of monomethoxypolyethylene glycol (PEG), molecular weight 5,000, covalently attached to the enzyme adenosine deaminase (ADA). ADA (adenosine deaminase EC 3.5.4.4) used in the manufacture
Prescribed forIt is used for Treating severe combined immunodeficiency disease (SCID) in certain patients with adenosine deaminase (ADA) deficiency.
Chemical Name(monomethoxypolyethylene glycol succinimidyl) 11-17_ adenosine deaminase
FormulationEach ml of ADAGEN injection contains, 250 units of Pegademase bovine, 20 mg of Monobasic sodium phoshphate, USP, 5.58 mg of Dibasic sodium phoshphate, USP, 8.50 mg of Sodiium chloride, USP and q.s. to 0 ml of water for injection.
Physcial AppearanceIsotonic, pyrogen free, Sterile solution, pH 7.2-7.4
Route of AdministrationIntramusular Injection
Recommended DosageThe dosage of ADAGEN (pegademase bovine) Injection should be individualized. The recommended dosing schedule is 10 U/kg for the first dose, 15 U/kg for the second dose, and 20 U/kg for the third dose. The usual maintenance dose is 20 U/kg per week. Further increases of 5 U/kg/week may be necessary, but a maximum single dose of 30 U/kg should not be exceeded.
ContraindicationAllergic
Side EffectsRash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; dark urine; severe or persistent tiredness or weakness; unusual bruising or bleeding
Useful Linkhttp://www.adagen.com/
PubMed ID18778113, 19707420, 18778113, 8160672, 1803799
3-D StructureTh1050 (View) or (Download)


Entry 2
(2) Primary information
ID1359
ThPP IDTh1050
Therapeutic Peptide/Protein NamePegademase bovine
SequenceMAQTPAFNKPKVELHVHLDGAIKPETILYYGRKRGIALPADTPEELQNII view full sequnce in fasta
Functional ClassificationIa
Molecular Weight40788.2
Chemical FormulaC1821H2834N484O552S14
Isoelectric Point5.33
Hydrophobicity-0.428
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionBovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life.
Indication/DiseaseFor treatment of adenosine deaminase deficiency
PharmacodynamicsUsed to replace deficient or inactive adenosine deaminase which leads to severe combined immunodeficiency disease (SCID). The enzyme is responsible for converting adenosine to inosine. In the absence of adenosine deaminase, the purine substrates adenosine 2-deoxyadenosine and their metabolites are actually toxic to lymphocytes thereby leading to diminished immune function.
Mechanism of ActionPegademase converts adenosine (toxic) to inosine (less toxic) by deamination. It also converts 2'-deoxyadenosine to 2'-deoxyinosine via deamination.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesEnzyme Replacement Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionPegloticase
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsHeadache; pain or redness at the injection site.
Useful Linkhttp://www.drugs.com/dosage/adagen.html
PubMed ID18778113, 19707420, 18778113, 8160672, 1803799
3-D StructureTh1050 (View) or (Download)


Entry 3
(3) Primary information
ID1360
ThPP IDTh1050
Therapeutic Peptide/Protein NamePegademase bovine
SequenceMAQTPAFNKPKVELHVHLDGAIKPETILYYGRKRGIALPADTPEELQNII view full sequnce in fasta
Functional ClassificationIa
Molecular Weight40788.2
Chemical FormulaC1821H2834N484O552S14
Isoelectric Point5.33
Hydrophobicity-0.428
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionBovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life.
Indication/DiseaseFor treatment of adenosine deaminase deficiency
PharmacodynamicsUsed to replace deficient or inactive adenosine deaminase which leads to severe combined immunodeficiency disease (SCID). The enzyme is responsible for converting adenosine to inosine. In the absence of adenosine deaminase, the purine substrates adenosine 2-deoxyadenosine and their metabolites are actually toxic to lymphocytes thereby leading to diminished immune function.
Mechanism of ActionPegademase converts adenosine (toxic) to inosine (less toxic) by deamination. It also converts 2'-deoxyadenosine to 2'-deoxyinosine via deamination.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesEnzyme Replacement Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019818s042lbl.pdf
PubMed ID18778113, 19707420, 18778113, 8160672, 1803799
3-D StructureTh1050 (View) or (Download)